SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients

Pharmacogenomics

Volumn 11, Issue 12, 2010, Pages 1703-1713

  Michelon, Hugues ^a   König, Jörg ^b   Durrbach, Antoine ^b   Quteineh, Lina ^a   Verstuyft, Céline ^a   Furlan, Valérie ^a   Ferlicot, Sophie ^a   Letierce, Alexia ^a   Charpentier, Bernard ^c   Fromm, Martin F ^b   Becquemont, Laurent ^a  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

adverse drug reaction; genetic polymorphism; mycophenolic acid; OATP1B1; pharmacogenetics; renal transplantation; SLCO1B1

Indexed keywords

CYCLOSPORIN A; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; INOSINATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORGANIC ANION TRANSPORTER 2; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALLELE; ANEMIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HEARTBURN; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOID HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; RECTUM HEMORRHAGE; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

BIOTRANSFORMATION; CELL LINE; DNA; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ORGANIC ANION TRANSPORTERS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SUBSTRATE SPECIFICITY; TRANSFECTION;

EID: 78650335300     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.132     Document Type: Article

References (51)

1. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C: Mycophenolate mofetil in renal allograft recipients: a pooled effcacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The international mycophenolate mofetil renal transplant study groups. Transplantation 63(1), 39-47 (1997).
2. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2-3), 85-118 (2000).
3. Knoll GA, Macdonald I, Khan A, Van Walraven C: Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J. Am. Soc. Nephrol. 14(9), 2381-2386 (2003).
4. Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet. 46(1), 13-58 (2007).
5. Detailed review on mycophenolic acid (MPA), MPA-phenyl-glucuronide and MPA-acyl-glucuronide.
6. Bullingham RE, Nicholls AJ, Kamm BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34(6), 429-455 (1998).
7. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by cyp3a4/5. Ther. Drug Monit. 26(6), 600-608 (2004).
8. Schutz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M: Identifcation of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin. Chem. 45(3), 419-422 (1999). (Pubitemid 29114183)
9. Shipkova M, Armstrong VW, Wieland E et al.: Identifcation of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br. J. Pharmacol. 126(5), 1075-1082 (1999). (Pubitemid 29123740)
10. Shipkova M, Strassburg CP, Braun F et al.: Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br. J. Pharmacol. 132(5), 1027-1034 (2001).
11. Nicholls AJ: Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/ pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin. Biochem. 31(5), 329-333 (1998).
12. Premaud A, Debord J, Rousseau A et al.: A double absorption-phase model adequately describes mycophenolic acid plasma profles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin. Pharmacokinet. 44(8), 837-847 (2005).
13. Van Gelder T, Le Meur Y, Shaw LM et al.: Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug Monit. 28(2), 145-154 (2006).
14. Barraclough KA, Staatz CE, Isbel NM, Johnson DW: Therapeutic monitoring of mycophenolate in transplantation: is it justifed? Current Drug Metabolism 10(2), 179-187 (2009).
15. Le Meur Y, Buchler M, Thierry A et al.: Individualized mycophenolate mofetil dosing, based on drug exposure, signifcantly improves patient outcomes after renal transplantation. Am. J. Transplant 7(11), 2496-2503 (2007).
16. Van Gelder T, Silva HT, De Fijter JW et al.: Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fxed-dose concentration-controlled trial. Transplantation 86(8), 1043-1051 (2008).
17. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C: Infuence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab. Dispos. 34(9), 1539-1545 (2006).
18. Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P: Infuence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-mpag production in vitro and in adult renal transplant patients. Pharmacogenet. Genomics 17(5), 321-330 (2007).
19. Kagaya H, Inoue K, Miura M et al.: Infuence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(3), 279-288 (2007). (Pubitemid 46233156)
20. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y: The impact of uridine diphosphate-glucuronosyltransferase 1a9 (UGT1A9) gene promoter region single-nucleotide polymorphisms t275a and c2152t on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 78(4), 351-361 (2005).
21. Levesque E, Delage R, Benoit-Biancamano MO et al.: The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profle of mycophenolic acid after a single oral dose in healthy volunteers. Clin. Pharmacol. Ther. 81(3), 392-400 (2007).
22. Miura M, Kagaya H, Satoh S et al.: Infuence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther. Drug Monit. 30(5), 559-564 (2008).
23. Miura M, Satoh S, Inoue K et al.: Infuence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(12), 1161-1169 (2007). (Pubitemid 350112768)
24. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y: Multidrug resistance protein 2 genetic polymorphisms infuence mycophenolic acid exposure in renal allograft recipients. Transplantation 82(8), 1074-1084 (2006).
25. Prausa S, Fukuda T, Maseck D et al.: UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 85(5), 495-500 (2009).
26. Van Agteren M, Armstrong VW, Van Schaik RH et al.: Acylmpag plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther. Drug Monit. 30(4), 439-444 (2008).
27. Wang J, Figurski M, Shaw LM, Burckart GJ: The impact of P-glycoprotein and MRP2 on mycophenolic acid levels in mice. Transpl. Immunol. 19(3-4), 192-196 (2008).
28. Picard N, Yee SW, Woillard JB et al.: The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther. 87(1), 100-108 (2009)
29. Wang J, Yang J W, Zeevi A et al.: IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin. Pharmacol. Ther. 83(5), 711-717 (2008).
30. Quteineh L, Verstuyft C, Durrbach A et al.: Impact of VKORC1 haplotypes on long-term graft function in kidney transplantation. Transplantation 86(6), 779-783 (2008).
31. Quteineh L, Verstuyft C, Furlan V et al.: Infuence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol. 103(6), 546-552 (2008).
32. Solez K, Colvin RB, Racusen LC et al.: Banff 2005 meeting report: differential diagnosis of chronic allograft injury and imination of chronic allograft nephropathy Am. J. Transplant 7(3), 518-526 (2007).
33. Oswald S, Konig J, Lutjohann D et al.: Disposition of ezetimibe is infuenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet. Genomics 18(7), 559-568 (2008).
34. Seithel A, Eberl S, Singer K et al.: The infuence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 35(5), 779-786 (2007).
35. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, mrp2, permanently expressed in human and canine cells. Mol. Pharmacol. 55(5), 929-937 (1999).
36. Tregouet DA, Garelle V: A new java interface implementation of thesias: Testing haplotype effects in association studies. Bioinformatics 23(8), 1038-1039 (2007).
37. Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78(3), 260-277 (2005).
38. Niemi M: Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8(7), 787-802 (2007).
39. Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: Identifcation of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276(38), 35669-35675 (2001).
40. Niemi M, Schaeffeler E, Lang T et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-c (OATP-C, SLCO1B1). Pharmacogenetics 14(7), 429-440 (2004).
41. Link E, Parish S, Armitage J et al.: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
42. Heller T, Van Gelder T, Budde K et al.: Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am. J. Transplant 7(7), 1822-1831 (2007).
43. Woillard JB: Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: The signifcant role of the UGT1A8*2 variant allele. Br. J. Clin. Pharmacol. 69(6), 675-683 (2010).
44. Hesselink DA, Van Hest RM, Mathot RA et al.: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J Transplant 5(5), 987-994 (2005).
45. Grinyo JM, Ekberg H, Mamelok RD et al.: The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The symphony pharmacokinetic substudy Nephrol. Dial. Transplant 24(7), 2269-2276 (2009).
46. Simonson SG, Raza A, Martin PD et al.: Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76(2), 167-177 (2004).
47. Yau WP, Vathsala A, Lou HX, Zhou S, Chan E: Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in asian renal transplant patients. J. Clin. Pharmacol. 49(6), 684-699 (2009).
48. Van Schaik R, Van Agteren M, De Fijter J et al.: UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low mpa exposure and acute rejection in MMF/ tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86(3), 319-327 (2009).
49. Betonico GN, Abbud-Filho M, Goloni-Bertollo EM et al.: Infuence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients. Transplant. Proc. 40(3), 708-710 (2008).
50. Glander P, Hambach P, Braun KP et al.: Effect of mycophenolate mofetil on IMP dehydrogenase after the frst dose and after long-term treatment in renal transplant recipients. Int. J. Clin. Pharmacol. Ther. 41(10), 470-476 (2003).
51. Sombogaard F, Van Schaik RH, Mathot RA et al.: Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. Pharmacogenet. Genomics 19(8), 626-634 (2009).